Optiver Holding
DSGN icon

Optiver Holding’s Design Therapeutics DSGN Stock Holding History

Optiver Holding’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31K Sell
160
-64
-29% -$798 ﹤0.01% 2267
2026
Q1 		$2.38K Sell
224
-104
-32% -$1.05K ﹤0.01% 1773
2025
Q4 		$3.08K Hold
328
– – ﹤0.01% 1737
2025
Q3 		$2.47K Buy
+328
New +$1.64K ﹤0.01% 2295

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Optiver Holding's DSGN Position: Q2 2026 in Review

Optiver Holding reduced its Design Therapeutics (DSGN) stake by 29% in Q2 2026, selling an estimated $798 and leaving 160 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Optiver Holding first reported a position in DSGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.08K in Q4 2025. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Optiver Holding held 160 shares of Design Therapeutics worth $2.31K as of Q2 2026.
  • Optiver Holding sold 64 Design Therapeutics shares in Q2 2026, an estimated $798.
  • Design Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2267 holding.
  • Optiver Holding first reported a position in Design Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Design Therapeutics position peaked at $3.08K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.